Experimental Alzheimer’s Drug Slows Mental Decline By 27% in Trial Hailed as ‘Most Encouraging to Date’

Biogen and Eisai released their phase 3 trial results, showing new Alzheimer’s drug lecanemab slowed the rate of cognitive decline by 27%.

Source: Experimental Alzheimer’s Drug Slows Mental Decline By 27% in Trial Hailed as ‘Most Encouraging to Date’

I know there have been a few setbacks in the Alzheimer’s research arena, so it’s encouraging to see progress continues to be made.